A Phase II Study of Transarterial Chemoembolisation and Axitinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2018
At a glance
- Drugs Axitinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 19 Jun 2018 Status changed from active, no longer recruiting to completed.
- 05 Jul 2017 Planned End Date changed from 1 May 2017 to 31 May 2018.
- 05 Jul 2017 Planned primary completion date changed from 1 May 2017 to 31 May 2018.